<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774003</url>
  </required_header>
  <id_info>
    <org_study_id>CKJX839A12105</org_study_id>
    <nct_id>NCT04774003</nct_id>
  </id_info>
  <brief_title>Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C</brief_title>
  <acronym>ORION-14</acronym>
  <official_title>A Placebo-controlled, Participant, Investigator and Sponsor Blinded, Randomized Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Inclisiran Treatment Given as Single Subcutaneous Injection in Chinese Participants With Elevated Low-density Lipoprotein Cholesterol (LDL-C) Despite Treatment With LDL-C Lowering Therapies (ORION-14)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as&#xD;
      single subcutaneous injection in Chinese participants with elevated low-density lipoprotein&#xD;
      cholesterol (LDL-C) despite treatment with LDL-C lowering therapies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to characterize pharmacokinetics, pharmacodynamics, safety and&#xD;
      tolerability of inclisiran in Chinese participants with elevated serum LDL-C to support&#xD;
      inclisiran registration in China.Inclisiran is a long acting RNA therapeutic agent that&#xD;
      inhibits the synthesis of PCSK9, leading to reduced circulating LDL-C levels. Three pivotal&#xD;
      Phase III studies have been conducted primarily in non-Asian participants to support New Drug&#xD;
      Application/Marketing Authorization Application approval of inclisiran globally. This study&#xD;
      design is based on the hypothesis that the global inclisiran clinical data primarily obtained&#xD;
      in Caucasian participants could be appropriately extrapolated to Chinese participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">December 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a placebo-controlled study of inclisiran sodium given as a single subcutaneous injection of either 100 mg and 300 mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a participant, investigator and sponsor blinded, randomized study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters (Cmax) maximum peak observed plasma inclisiran concentration in treated participants</measure>
    <time_frame>0-48 hours post-dose</time_frame>
    <description>Pharmacokinetics parameters of inclisiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (Tmax) time to reach maximum peak plasma inclisiran concentration in treated participants</measure>
    <time_frame>0-48 hours post-dose</time_frame>
    <description>Pharmacokinetics parameters of inclisiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (T1/2) the elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve in inclisiran treated participants</measure>
    <time_frame>0-48 hours post-dose</time_frame>
    <description>Pharmacokinetics parameters of inclisiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (AUC) area under the plasma concentration-time curve in inclisiran treated participants</measure>
    <time_frame>0-48 hours post-dose</time_frame>
    <description>Pharmacokinetics parameters of inclisiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change in Proprotein convertase subtilisin kexin 9 (PCSK9) from baseline overtime</measure>
    <time_frame>Baseline to Days 5, 8, 15, 30, 60 and 90</time_frame>
    <description>Pharmacodynamics effects of inclisiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change in Low density lipoprotein cholesterol (LDL-C) from baseline overtime</measure>
    <time_frame>Baseline to Days 5, 8, 15, 30, 60 and 90</time_frame>
    <description>Pharmacodynamics effects of inclisiran</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to Days 30, 60 and 90 in PD parameter Proprotein convertase subtilisin kexin 9 (PCSK9)</measure>
    <time_frame>Baseline to Days 30, 60 and 90</time_frame>
    <description>Pharmacodynamics differences between inclisiran and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to Days 30, 60 and 90 in PD parameter Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline to Days 30, 60 and 90</time_frame>
    <description>Pharmacodynamics differences between inclisiran and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of formation of anti-drug antibodies to Inclisiran</measure>
    <time_frame>Baseline, Days 30 and 90</time_frame>
    <description>Immunogenicity of inclisiran</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>300 mg inclisiran sodium (equivalent to 284 mg inclisiran)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo x 1 dose (n=10) at Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)</intervention_name>
    <description>100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1</description>
    <arm_group_label>100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)</arm_group_label>
    <other_name>KJX839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg inclisiran sodium (equivalent to 284 mg inclisiran)</intervention_name>
    <description>300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1</description>
    <arm_group_label>300 mg inclisiran sodium (equivalent to 284 mg inclisiran)</arm_group_label>
    <other_name>KJX839</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          2. Male or female participants ≥ 18 years of age at screening&#xD;
&#xD;
          3. Participants should meet fasting serum LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L) at screening&#xD;
&#xD;
          4. Participants should meet fasting triglyceride &lt; 400 mg/dL (&lt; 4.52 mmol/L) at screening&#xD;
&#xD;
          5. Participants should be receiving a maximally tolerated dose of statin#.&#xD;
&#xD;
          6. For all participants, all the lipid-lowering therapy/ies (such as but not limited to&#xD;
             statins and/or ezetimibe) should have remained stable (stable dose and no medication&#xD;
             change) for ≥ 30 days before screening with no planned medication or dose change&#xD;
             during study participation. #Maximum tolerated dose was defined as the maximum dose of&#xD;
             statin that could be taken on a regular basis without intolerable AEs.&#xD;
&#xD;
          7. Participants not receiving statin must have a documented evidence of intolerance to&#xD;
             all doses of at least 2 different statins (or the corresponding local definition of&#xD;
             complete intolerance to statins)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants diagnosed with any of following: homozygous familial&#xD;
             hypercholesterolemia, New York Heart Association class III &amp; IV heart failure, Type 2&#xD;
             diabetes, severe hypertension, active liver disease, HIV infection or any uncontrolled&#xD;
             or serious disease;&#xD;
&#xD;
          2. History of drug abuse or unhealthy alcohol use, malignancy of any organ system, or or&#xD;
             allergy to the investigational compound/compound class;&#xD;
&#xD;
          3. Major adverse cardiovascular event within 3 months prior to randomization;&#xD;
&#xD;
          4. Calculated glomerular filtration rate ≤30 mL/min by estimated glomerular filtration&#xD;
             rate (eGFR) using standardized clinical methodology;&#xD;
&#xD;
          5. Use of other investigational drugs or planned use of other investigational products or&#xD;
             devices;&#xD;
&#xD;
          6. Women of child-bearing potential unless they are using basic methods of contraception&#xD;
             during dosing of investigational drug (total abstinence, sterilization, barrier&#xD;
             methods, hormonal contraception, intrauterine device);&#xD;
&#xD;
          7. Treatment with monoclonal antibodies inhibiting PCSK9 within 90 days prior to&#xD;
             screening.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inclisiran</keyword>
  <keyword>KJX839</keyword>
  <keyword>LDL-C</keyword>
  <keyword>Pharmacokinetics and pharmacodynamics</keyword>
  <keyword>Chinese participants with elevated serum LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

